How does the breast cancer risk associated with Premique Low Dose relate to treatment duration?

With Premique Low Dose, increased breast cancer risk depends on treatment duration, becoming apparent after about 3 (1–4) years; after stopping, excess risk decreases over time, but return to baseline depends on prior treatment duration, and risk may persist for 10 years or more after use exceeding 5 years.